arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Opus Genetics, Inc.

IRD
$4.82 ▼ -0.32 (-6.23%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
76 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
40
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

Opus Genetics, Inc. faces fundamental challenges. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $460.2M
Dividend Yield —
Revenue Growth -73.8% ↘
Op. Margin None
ROIC -73.9% ↘
FCF / Share $-0.13 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -2.72
info Valuation on last close. End-of-day price, Sep 23, 2026.

76-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$755.00K
↓ -73.8% —
Net Income Profit after all expenses
$-65.53M
↓ -699.8% —
Operating Margin Operating profit as % of sales
-296.3%
↓ -9.8% 0th
FCF / Share Free cash flow per share
$-0.13
↑ +14.6% —
Long-Term Debt Long-term obligations
$35.28M
↑ +2845.0% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Financial Health
85
Cash Quality ↑
49

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 25 years · 76 quarters